Archief longkankerstudies in Nederland
Op deze pagina vindt u een overzicht van de afgeronde longkankerstudies van de aangesloten centra. Maak gebruik van de zoek- en filterfunctie om eenvoudig door het aanbod van de afgeronde longkankerstudies te navigeren.
1479.0001 BI (Beamion Lung)
LUMC
Open label, fase 1 dosis escalatie (1a) en expansie studie (1b)
ARTEMIDE-01
LUMC
Open label, fase 1/ 2 dosis escalatie en expansie studie
Amaze-lung
Antoni van Leeuwenhoek
A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI
Amgen Tarlatamab - Dellphi304
LUMC
Open label, gerandomiseerde fase 3 studie
DF1001 – A phase I/II, first-in-human, multi-part, open-label, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expanding in selected indications.
Radboud UMC
Non-randomized, open-label expansion study.
GDC-6036 + Pembrolizumab
Antoni van Leeuwenhoek
OPEN-LABEL
IMMUCAN
MUMC+
moleculaire profiling van solide tumoren
POTENTIA
Amsterdam UMC
A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours
STAR-121 (Gilead GS-US-626-6216)
UMC Groningen and Erasmus MC